On February 23, 2026 Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, reported a license agreement and equity partnership with Solstice Oncology, a clinical stage biotechnology company established by a syndicate of major venture capital investors, for the exclusive development and commercialization of a clinical stage portfolio asset HBM4003 outside Greater China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the license agreement, Harbour BioMed will receive upfront consideration valued at over $105 million, comprised of $50 million in upfront payments, $5 million in near-term cash payments and over $50 million of equity in Solstice. Harbour BioMed is also eligible for additional development, regulatory and commercial milestones up to approximately $1.1 billion, contingent on the achievement of certain future events, and tiered royalties on net sales outside Greater China.
"Harbour BioMed has built a significant reputation in the discovery and development novel therapeutic antibodies," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "This partnership is a reflection of that experience, and the structure goes beyond a traditional licensing transaction. By co-founding a company along with others and becoming a shareholder, we are participating in the building of a global biotechnology company alongside experienced investors, focused on the development of HBM4003, one of our leading antibody programs. This structure enables long-term value creation while allowing Harbour BioMed to remain engaged in advancing the asset toward global development."
(Press release, Harbour BioMed, FEB 23, 2026, View Source [SID1234670662])